SGLT2, a glucose transporter in the kidney's proximal tubule, is primarily involved in glucose reabsorption. SGLT2 inhibitors prevent this reabsorption, leading to glucose excretion in urine and glycemic control. These inhibitors also have a secondary effect of lowering blood pressure, independent of glucose levels. Recent research has identified SGLT2 in the central nervous system, particularly in areas regulating cardiorespiratory functions, suggesting a broader role in blood pressure regulation. SGLT2 inhibitors may influence blood pressure through mechanisms such as osmotic diuresis, natriuresis, and sympathetic nervous system modulation. Studies show that SGLT2 inhibitors reduce blood pressure in both diabetic and non-diabetic individuals, with effects comparable to conventional antihypertensive drugs. The presence of SGLT2 in the brain, especially in the nucleus of the solitary tract (nTS), indicates its potential role in central autonomic control. Research suggests that SGLT2 may regulate blood pressure in the nTS through mechanisms distinct from those in the kidney. SGLT2 inhibitors have shown promise in treating hypertension, with clinical trials demonstrating significant blood pressure reduction. Further studies are needed to fully understand the mechanisms of SGLT2 in the brain and its potential for novel therapeutic applications in blood pressure regulation.SGLT2, a glucose transporter in the kidney's proximal tubule, is primarily involved in glucose reabsorption. SGLT2 inhibitors prevent this reabsorption, leading to glucose excretion in urine and glycemic control. These inhibitors also have a secondary effect of lowering blood pressure, independent of glucose levels. Recent research has identified SGLT2 in the central nervous system, particularly in areas regulating cardiorespiratory functions, suggesting a broader role in blood pressure regulation. SGLT2 inhibitors may influence blood pressure through mechanisms such as osmotic diuresis, natriuresis, and sympathetic nervous system modulation. Studies show that SGLT2 inhibitors reduce blood pressure in both diabetic and non-diabetic individuals, with effects comparable to conventional antihypertensive drugs. The presence of SGLT2 in the brain, especially in the nucleus of the solitary tract (nTS), indicates its potential role in central autonomic control. Research suggests that SGLT2 may regulate blood pressure in the nTS through mechanisms distinct from those in the kidney. SGLT2 inhibitors have shown promise in treating hypertension, with clinical trials demonstrating significant blood pressure reduction. Further studies are needed to fully understand the mechanisms of SGLT2 in the brain and its potential for novel therapeutic applications in blood pressure regulation.